Treating MGD and evaporative dry eye

Article

Evaluation of a new system

In a recent study,1 Dr Cati Albou-Ganem (Centre National d'Ophthalmologie des Quinze-Vingts, Paris, France) and Dr R. Amar evaluated a new system (LipiFlow, TearScience, Morrisville, North Carolina, USA) to treat patients with meibomian gland dysfunction (MGD) and evaporative dry eye. "I was very interested by the performance of the diagnostic platform and thought that our dry eye patients desperately needed a solution for their problem," she said.

Evaluating a new system

"We selected patients using the SPEED (Standard Patient Evaluation of Eye Dryness) questionnaire," explained Dr Albou-Ganem. "This questionnaire allows the patient to describe their symptoms easily." All patients studied were suffering from dry eye without any surgical impact and any patient that had a score higher than 6 (out of 28) from the questionnaire were selected to have the lipid layer of their eyes analysed.

"First, the LipiView (TearScience) exam allowed us to measure the lipid layer thickness," continued Dr Albou-Ganem. It has been demonstrated that a thin lipid layer (below 70 nm) is correlated to the symptoms of dry eye, she noted.

"When the lipid layer was below 70 we analysed the functionality of the meibomian glands using the Meibomian Gland Evaluator (MGE)," she said. "The MGE allows us to apply a constant force to the lid, mimicking the force of a deliberate blink. Therefore, we can observe the secretions expressed at each blink. For the first time, we were able to reproducibly look at secretions."

If the number of meibomian glands capable of secreting clear and liquid lipids was below 5 (out of 15 that were observed), Dr Albou-Ganem and Dr Amar confirmed diagnosis that the patient was experiencing evaporative dry eye as a result of MGD. A direct correlation between the number of functioning glands and the symptoms of dry eye has also been previously demonstrated.2,3

LipiFlow treatment

Once the patient had been confirmed as having evaporative dry eye as a result of MGD, the team used the LipiFlow treatment, which has been designed to unblock the meibomian glands and restore their function. "This system applies a constant heat to the posterior face of the lids during 12 minutes and a series of pulsations on the outer face of the lids in order to massage them," added Dr Albou-Ganem.

"By applying the right temperature and a moderate pressure, it is not painful for the patients and very efficient," she continued. "Post-treatment we could observe a significant improvement in the gland function."

Application of a constant temperature is also important, she explained as a temperature of 42.5 °C is necessary to liquefy the secretions that block the glands. "It is important to note that this temperature is not only applied to the lid margin but to the whole surface of the posterior lids, unblocking the glands in their depth," Dr Albou-Ganem asserted.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.